Massachusetts Cannabis Audit Reveals 13% of Flower Products Mislabeled for THC Potency

A Massachusetts Cannabis Control Commission audit of 63 cannabis flower products found approximately 13% tested outside acceptable THC variation limits, with labels requiring accuracy within 75-125% of stated potency. The findings highlight quality control gaps in cannabis production and labeling practices that could affect patient dosing, particularly for medical marijuana users treating conditions like chronic pain, anxiety, and insomnia. Accurate potency labeling is critical for patients to safely self-titrate doses and achieve therapeutic benefits. These results underscore the importance of robust testing standards and regulatory oversight in cannabis markets, including emerging programs in Puerto Rico.